Essai clinique NCT05920356 · Non-Small Cell Lung Cancer (NSCLC)
Recherche en oncologie
14/09/2026
Essai clinique NCT05920356 (phase III) est «en recrutement» sur ClinicalTrials.gov.
Pathologie: Non-Small Cell Lung Cancer (NSCLC) · Interventions enregistrées: Sotorasib, Pembrolizumab · Dates enregistrées (source): 2023-11-16, 2027-06-30, 2023-06-27, 2026-09-11.
Résumé de l’étude (source : ClinicalTrials.gov, texte original en anglais):
The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet chemotherapy.